Clinical trial · Observational
E- Predict: EBUS ELASTOGRAPHY STRAIN in Lung Cancer
E-PREDICT Evaluating the Predictive Value of EBUS ELASTOGRAPHY STRAIN in Patients With (Suspected) Lung Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
EBUS elastography is a method to determine stiffness of lymph nodes, based on the minute deformation of the node by the beating heart. Whether EBUS elastography may further increase the sensitivity to predict the presence or absence of malignancy is unclear. We suggest to use EBUS elastography strain pattern analysis for this assessment and correlate these measurements with the final pathology outcome to determine NPV, PPV, sensitivity and specificity of this analysis to predict the presence or absence of malignancy in patients with (suspected) lung cancer in a prospectively obtained observational cohort study.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- stiffness of lymph nodes
- timeFrame
- participants will be followed for the duration of hospital stay, an expected average of 4 hours
- description
- stiffness/strain is a relative measure and has therefor no units
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with indication for diagnostic or staging EBUS procedure for suspected or proven lung cancer. * ASA physical status 1-3. * Age 18 years or older. Exclusion Criteria: * Bleeding disorders. * Contra-indication for temporary interruption of the use of anticoagulant therapy (acenocoumarol, warfarin, therapeutic dose of low molecular weight heparines or clopidrogel). * Known allergy for lidocaine. * Uncontrolled pulmonary hypertension. * Recent and/or uncontrolled cardiac disease. * Compromised upper airway (eg concomitant head and neck cancer or central airway stenosis for any reason). * Prior radiotherapy treatment involving the central airways * ASA classification greater than or equal to 4. * Pregnancy. * Inability to consent.
References
Publications (0)
Data not yet available